Physician profile
Keith L Stroder
NPI 1487183067
$6,710.81
in general payments reported to CMS, 2019-2025
27 companies · $1,577 in 2025
The $1,577 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $921 · 2022: $1,369 · 2023: $1,243 · 2024: $1,600 · 2025: $1,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,421.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,614.52 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,119.32 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $839.94 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Axsome Therapeutics, INC. | $650.24 | 2024-2025 | Auvelity |
| Pfizer INC. | $466.21 | 2022-2025 | |
| Sunovion Pharmaceuticals INC. | $441.25 | 2021-2022 | |
| Exact Sciences Corporation | $289.06 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Urovant Sciences INC | $243.11 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $139.61 | 2022 | |
| Sumitomo Pharma America, INC. | $138.63 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.60 | 2022-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $109.61 | 2025 | Rexulti |
| Dexcom, INC. | $84.28 | 2022-2023 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $64.74 | 2023-2025 | Zepbound, Emgality, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $63.77 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $59.31 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Mylan Specialty L.P. | $50.25 | 2021-2023 | Yupelri |
| Amgen INC. | $36.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $28.48 | 2025 | |
| Alkermes, INC. | $27.50 | 2023 | Vivitrol |
| Abbott Laboratories | $23.00 | 2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.75 | 2022 | |
| Organogenesis INC. | $17.73 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.19 | 2024 | Voquezna |
| Astellas Pharma US INC | $14.41 | 2021 | |
| Biogen, INC. | $13.42 | 2021 | |
| Corium, LLC | $6.30 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Stroder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.